Welcome to CDC stacks | Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia - 35555 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
Filetype[PDF-904.33 KB]


Details:
No Related Documents.
You May Also Like:
  1. Invasive Streptococcus pneumoniae in Children, Malawi, 2004–2006
    Personal Author:
    Cornick, Jennifer E.; Everett, Dean B.; Broughton, Caroline; Denis, Brigitte B.; Banda, Daniel L.; Carrol, Enitan D.; Parry, Christopher M.;
    Published:
    Jun 2011
    Source:
    Emerg Infect Dis. 17(6):1107-1109.
    Description:
    Of 176 invasive Streptococcus pneumoniae isolates from children in Malawi, common serotypes were 1 (23%), 6A/B (18%), 14 (6%), and 23F (6%). Coverage with the 7-valent pneumococcal conjugate vaccine (PCV) was 39%; PCV10 and PCV13 increased coverage t...
    File Type:
    Filetype[PDF - 156.51 KB]
  2. Incidence of Pneumococcal Pneumonia among Adults in Rural Thailand, 2006–2011: Implications for Pneumococcal Vaccine Considerations
    Personal Author:
    Piralam, Barameht; Tomczyk, Sara M.; Rhodes, Julia C.; Thamthitiwat, Somsak; Gregory, Christopher J.; Olsen, Sonja J.; Praphasiri, Prabda; Sawatwong, Pongpun; Naorat, Sathapana; Chantra, Somrak; Areerat, Peera; Hurst, Cameron P.; Moore, Matthew R.; Muangchana, Charung; Baggett, Henry C.;
    Published:
    Oct 26 2015
    Source:
    Am J Trop Med Hyg. 2015; 93(6):1140-1147.
    Description:
    The incidence of pneumococcal pneumonia among adults is a key driver for the cost-effectiveness of pneumococcal conjugate vaccine used among children. We sought to obtain more accurate incidence estimates among adults by including results of pneumoco...
    File Type:
    Filetype[PDF - 741.13 KB]
  3. MMWR. Morbidity and mortality weekly report, Vol. 54, no. 36, September 16, 2005
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    September 16, 2005
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 54, no. 36
    Description:
    Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease--United States, 1998-2003 -- Improper Disposal of Hazardous Substances and Resulting Injuries--S...
    File Type:
    Filetype[PDF - 462.20 KB]
  4. Prevention of pneumococcal disease among infants and children; use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Nuorti, J. Pekka.; Whitney, Cynthia G.;
    Corporate Author:
    United States, Advisory Committee on Immunization Practices.; Centers for Disease Control and Prevention (U.S.); National Center for Immunization and Respiratory Diseases (U.S.), Division of Bacterial Diseases.;
    Published:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneum...
    File Type:
    Filetype[PDF - 569.96 KB]
  5. Prevention of pneumococcal disease among infants and children; use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Nuorti, J. Pekka; Whitney, Cynthia G.;
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.; Centers for Disease Control and Prevention (U.S.); National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.;
    Published:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneum...
    Status:
    current
    File Type:
    Filetype[PDF - 569.96 KB]